|
|
|
|
|
|
|
|
|
|
press release
March 19, 2013 /PRNewswire/ -- EGEN, Inc. today announced that it has recently initiated a Phase I clinical trial of its novel immunotherapy agent, EGEN-001, in combination with PEGylated liposomal Doxorubicin or Lipodox for the treatment of recurrent ovarian cancer. The EGEN-sponsored trial is conducted by a network of researchers led by Gynecologic Oncology Group (GOG) at member institutions under an agreement between the GOG and EGEN, Inc. Dr. Premal Thaker , of Washington University School of Medicine, is the Study Chair for the trial.......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.